Who is sponsoring NCT03368937?

NCT03368937 is sponsored by University of Virginia.

What drugs are being tested in NCT03368937?

Interventions in NCT03368937: Tandem t:slim X2 with Control-IQ Technology.

What condition does NCT03368937 study?

NCT03368937 studies Type1 Diabetes Mellitus.

Is NCT03368937 still recruiting?

NCT03368937 is currently completed. Last updated 25 May 2022.

Are results published for NCT03368937?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-05-25 · How we verify

NCT03368937

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Test of t:Slim X2 With Control-IQ Technology

Completed NA Results posted Last updated 25 May 2022

What this trial tests

NA trial testing Tandem t:slim X2 with Control-IQ Technology in Type1 Diabetes Mellitus in 5 participants. Completed in 11 December 2017.

Timeline

8 December 2017

Primary endpoint
11 December 2017

11 December 2017

Quick facts

Lead sponsor	University of Virginia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	5
Start date	8 December 2017
Primary completion	11 December 2017
Estimated completion	11 December 2017
Sites	1 location across United States

Drugs / interventions tested

Tandem t:slim X2 with Control-IQ Technology

Conditions studied

Type1 Diabetes Mellitus — all drugs for Type1 Diabetes Mellitus →

Sponsor

University of Virginia

Who can join

Adults 18 to 74, any sex, with Type1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

System Suitability Primary · 36-48 hours

Technology Acceptance Questionnaire Score Scores are on a Likert Scale of 1-Not at All to 5-Extremely for Ease of Use, Usability and Trust in System Scores.

Ease of Use

Group	Value	95% CI
Tandem t:Slim X2 With Control-IQ Technology	5	5 – 5

Usefulness

Group	Value	95% CI
Tandem t:Slim X2 With Control-IQ Technology	4.8	4 – 5

Trust in System

Group	Value	95% CI
Tandem t:Slim X2 With Control-IQ Technology	5	5 – 5

Sponsor's own description

A 36-48 hour admission testing the t:slim X2 with Control-IQ Technology

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

First Look at Control-IQ: A New-Generation Automated Insulin Delivery System.
Brown S, Raghinaru D, Emory E, Kovatchev B. · · 2018 · cited 54× · PMID 30305346 · DOI 10.2337/dc18-1249

Verify or expand the search:

Other trials of Tandem t:slim X2 with Control-IQ Technology

Trials testing the same drug.

NCT05653518 — Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes · NA · recruiting

Other recruiting trials for Type1 Diabetes Mellitus

Currently open trials in the same condition.

NCT03945747 — MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus · active not recruiting
NCT03369821 — EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study) · recruiting
NCT03811470 — China Diabetes Registry by Metabolic Management Center · recruiting

Other University of Virginia trials

Trials by the same sponsor.

NCT05880355 — Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI · EARLY_PHASE1 · not yet recruiting
NCT07405645 — Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy · NA · recruiting
NCT07146685 — Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study · Phase 4 · not yet recruiting
NCT07298941 — Resilience Enhancement Following Sleep Treatment · Phase 2 · recruiting
NCT07036315 — Meaning in Music-Based Pain Modulation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03368937 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Virginia
Last refreshed: 25 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03368937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing